Abstract
Zinc concentrates in islet cells and is related to insulin secretion. Islet cells act as a unit within islets and hormone secretion in the islets is profoundly influenced by paracrine and autocrine regulation. Zinc has been recognised as a candidate paracrine inhibitor of glucagon secretion in α-cells. Further zinc fluxes may contribute to regulation of cell mass, Zn2+ may be cytotoxic and Zn2+ depletion by itself can cause cell death induced by oxidative stress. Recently, both free zinc ions and a number of zinc transporters have been localized in α-cells. These include zinc importers, ZIP1, ZIP10, and ZIP14 of the SLC39A family and zinc exporters, ZnT1, and ZnT4-8 of the SLC30A family. Furthermore, the redox state of thiol groups and Voltage Gated Ca2+ Channels (VGCC) add to the maintenance of a tight cytoplasmatic zinc homeostasis in the α-cells. The ZnT8 protein has emerged as particularly interesting since this zinc transporter has been identified as a genetic risk factor for the development of both type 1 and type 2 diabetes in which both α- and β-cell functions are affected. Recent data discussed here suggest specific effects of Zn2+ on glucagon secretion and other α-cell functions.
Keywords: Pancreas, Diabetes, α-cells, Glucagon, Zinc transporters, Zn2+
Current Diabetes Reviews
Title: Zinc, Alpha Cells and Glucagon Secretion
Volume: 6 Issue: 1
Author(s): Laerke Egefjord, Andreas B. Petersen, Ann M. Bak and Jorgen Rungby
Affiliation:
Keywords: Pancreas, Diabetes, α-cells, Glucagon, Zinc transporters, Zn2+
Abstract: Zinc concentrates in islet cells and is related to insulin secretion. Islet cells act as a unit within islets and hormone secretion in the islets is profoundly influenced by paracrine and autocrine regulation. Zinc has been recognised as a candidate paracrine inhibitor of glucagon secretion in α-cells. Further zinc fluxes may contribute to regulation of cell mass, Zn2+ may be cytotoxic and Zn2+ depletion by itself can cause cell death induced by oxidative stress. Recently, both free zinc ions and a number of zinc transporters have been localized in α-cells. These include zinc importers, ZIP1, ZIP10, and ZIP14 of the SLC39A family and zinc exporters, ZnT1, and ZnT4-8 of the SLC30A family. Furthermore, the redox state of thiol groups and Voltage Gated Ca2+ Channels (VGCC) add to the maintenance of a tight cytoplasmatic zinc homeostasis in the α-cells. The ZnT8 protein has emerged as particularly interesting since this zinc transporter has been identified as a genetic risk factor for the development of both type 1 and type 2 diabetes in which both α- and β-cell functions are affected. Recent data discussed here suggest specific effects of Zn2+ on glucagon secretion and other α-cell functions.
Export Options
About this article
Cite this article as:
Egefjord Laerke, Petersen B. Andreas, Bak M. Ann and Rungby Jorgen, Zinc, Alpha Cells and Glucagon Secretion, Current Diabetes Reviews 2010; 6 (1) . https://dx.doi.org/10.2174/157339910790442655
DOI https://dx.doi.org/10.2174/157339910790442655 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantum Dots as Promising Theranostic Tools Against Amyloidosis: A Review
Protein & Peptide Letters Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
CNS & Neurological Disorders - Drug Targets Role of Nanotechnology in Diabetic Management
Recent Patents on Nanotechnology Synthesis and Antioxidant Evaluation of a New Class of Thienopyrimidine-rhodanine Hybrids
Letters in Drug Design & Discovery Lipoprotein-associated Phospholipase A2: A Potential Therapeutic Target for Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Women and Schizophrenia: Sex-Based Pharmacotherapy
Current Psychiatry Reviews Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Therapeutic Potentials and Cytochrome P450-Mediated Interactions Involving Herbal Products Indicated for Diabetes Mellitus
Drug Metabolism Letters Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Can Marine Omega 3 Fatty Acids Prevent and/or Treat Metabolic Syndrome?
Current Nutrition & Food Science MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Current Diabetes Reviews Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Autophagy to the Rescue
Current Neurovascular Research A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs
Current Pharmaceutical Design Porphyromonas Gingivalis Antigenic Determinants - Potential Targets for the Vaccine Development against Periodontitis
Infectious Disorders - Drug Targets